论文部分内容阅读
目的阐明Ferroportin1(FPN1)mRNA及蛋白在人胃癌、结直肠癌、乳腺癌、肺癌及肝癌等多种肿瘤组织与癌旁组织中的表达分布情况,为肿瘤的诊断和治疗寻找新的靶点。方法利用Oncomine数据库,对多种肿瘤组织及正常组织中FPN1 mRNA的表达情况进行挖掘及荟萃分析。同时,采用免疫组织化学方法,研究FPN1蛋白在人类胃癌、结直肠癌、乳腺癌、肺癌及肝癌肿瘤组织和癌旁组织中的表达。结果结果发现,经数据挖掘FPN1 mRNA在神经系统肿瘤、食管癌、畸胎瘤中表达上调;在白血病、肺癌、卵巢癌、前列腺癌中表达下调。FPN1蛋白在结肠及肝脏组织中表达相对较高(中度阳性),在被检测的五种肿瘤标本中,其表达均有不同程度降低,却仅在乳腺癌及肝癌中存在统计学差异(P<0.05)。结论免疫组化证实FPN1蛋白表达在乳腺癌及肝癌组织中显著降低,而芯片数据却未发现其mRNA表达的相同趋势,这可能提示转录后调节在FPN1的表达调节中发挥更为主要的作用,且其有望作为乳腺癌及肝癌的诊断及治疗新靶点。
Objective To elucidate the expression and distribution of the mRNA and protein of Ferroportin 1 (FPN1) in human gastric cancer, colorectal cancer, breast cancer, lung cancer and liver cancer, and to explore new targets for the diagnosis and treatment of tumors. Methods Oncomine database was used to explore and meta-analysis of the expression of FPN1 mRNA in various tumor tissues and normal tissues. Meanwhile, immunohistochemistry was used to study the expression of FPN1 protein in human gastric cancer, colorectal cancer, breast cancer, lung cancer, liver cancer and adjacent tissues. The results showed that FPN1 mRNA was up-regulated in nervous system tumors, esophageal cancer and teratoma through data mining and down-regulated in leukemia, lung cancer, ovarian cancer and prostate cancer. The expression of FPN1 protein in colorectal and liver tissues was relatively high (moderately positive). The expression of FPN1 protein was decreased in all the five tumor specimens tested, but only in breast cancer and liver cancer (P <0.05). Conclusions Immunohistochemistry showed that the expression of FPN1 protein was significantly decreased in breast cancer and HCC tissues, but the same trend was not found in the data of the chip. This may suggest that post-transcriptional regulation plays a more important role in the regulation of FPN1 expression, And it is expected to be a new target for the diagnosis and treatment of breast cancer and liver cancer.